Oregon Cancer

Expert voices in immuno-oncology from inside and outside Providence gather for a day of thought-provoking discussion, discovery and collaboration.

Explore new findings in cancer immunotherapy and clinical research from Providence at ASCO 2025.

Providence Cancer Institute is enrolling patients for two new immunotherapy trials targeting muscle-invasive urothelial cancer and advanced solid tumors.

The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.

Two studies for people with ER+/HER2- breast cancer are enrolling patients at Providence Cancer Institute.

Gary tells his story about the difficult journey back to the slopes of Mt. Hood after receiving life-saving surgery for pancreatic cancer.

This is an exciting new trial comparing robotic assisted laparoscopy to open hysterectomy and lymph node assessment for the treatment of early-stage cervical cancer.

Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.

Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.

Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.